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Lymphomas originate from the malignant transformation of lymphocytes and are common 
haematological malignancies in the Western world. The first lymphoma to be recognized was 
Hodgkin’s lymphoma (HL), described by Thomas Hodgkin in 1832; all other lymphomas are 
known as non-Hodgkin lymphomas (NLH). HL has a bimodal incidence curve, occurring most 
frequently in young age (between 15-35 years) and in patients over 55 years. Epstein Barr virus 
(EBV) positive cases are found especially in patients below 10 years of age and older than 60 (1). 
HL is characterized by the presence of large mono- or multinucleated Hodgkin cells and 
binucleated Reed-Stenberg (RS) cells that constitute usually only about 1% of the total cell in the 
tumour mass. Although RS cells derive from B cells, they lose most of their B cell phenotype: 
they lack expression of BCR, while CD40-CD40L, Epstein Barr virus-derived latent membrane 
protein (LMP1) and CD30 are expressed (2). In particular, CD30 is expressed at higher levels by 
HL/RS cells and a soluble form has been found in the serum of several HL patients (3). The 
soluble form of CD30 (sCD30) is generated by proteolytic cleavage of metalloproteinase calls 
ADAMs. It has been shown that ADAM10 is expressed in both HL lymph nodes and HL/RS cells, 
(4) promoting an immunosuppressive microenvironment. 
HRS cells show numerical and structural aberrations. In addition to the common gains and losses 
of specific chromosomal regions, a chromosomal translocation is recurrent, involving the major 
histocompatibility class II (MHC II) trans-activator gene locus that has been observed in several 
cases of HL. It should be noted that MHC peptide α and β are cleaved by metalloproteinases like 
CD30 as well. These soluble forms are present in the serum of cancer patients and their levels 
correlate with tumour stage and metastasis contributing also to tumour cell escape from natural 
killer (NK) cell-mediated immunosurveillance (5).  
 
Immune response and evasion mechanisms of HL 
The body defends itself against virus, bacteria and foreign substances through immune responses. 
We can identify two different immune response pathways: innate and adaptive response. The 
innate immune response works through the activation of myeloid cells, such as macrophages, and 
soluble factors including cytokines and complement, it is rapid and non-specific; the adaptive 
branch is the body’s immune response against specific antigens and for this reason it takes longer 
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to activate all the components involved. The antigen specific immune response includes antigen-
presenting cells (APC), T and B cells, antibodies and all the adaptive responses which require 
several steps. Evading immune system is a prerequisite for neoplastic progression and this ability 
is linked to the expression of several stress-induced molecules that are known as natural killer 
receptor group 2 ligands (NKG2DL). In non-pathological conditions NKG2L stimulate NKG2D 
on the surface of natural killer cells (NK) or gamma delta T cells (ɤδ-T) (4). The interaction 
between NKG2D-NKG2DL results in the release of granzyme and perforin and antitumor 
cytokines like tumour necrosis factor α (TNFα) to trigger antitumor immune response. Tumors, 
including lymphomas, may become invisible through several mechanisms. Raneros and co-
workers (6) highlight how stress molecules such as MICA and MICB can be cleaved in malignant 
cells by protein metalloproteases ADAM10 and protein disulphide isomerase family A, also 
known as ERp5 (7) and be released as soluble molecules; soluble NKG2DL thus masks NKG2D 
and the signal cannot be activated.  
In addition, HL/RS cells can be found in the presence of non-malignant inflammatory, 
mesenchymal cells, T and B lymphocytes, eosinophils, neutrophils and plasma cells, unable to 
induce an effective anti-tumour immune response and providing survival signals by secretion of 
cytokines and chemokines (8) (9). It has been described that HL mesenchymal stromal cells 
(MSC) express very low levels of MICA and MICB, while high expression of metalloproteases 
and isomerases, in particular ADAM10 and ERp5, is observed. Since ADAM10 and ERp5 are 
both correlated with the shedding of stress molecules, including NKG2DL, we can hypothesize 
that microenvironment and cell interaction in HL play an important role in determining an anti-
tumor immune response (4). In addition, genetic modifications cooperate with microenvironment 
signalling in the activation of pro-tumoral pathways like Nuclear Factor-Kappaβ (NF-Kβ) and 
JACK-STAT. Different mechanism can be described related with NF-Kβ pathways. For instance, 
Epstein-Barr virus (EBV) is consistently associated with HL in 40% of cases (10). EBV virus 
Latent Membrane Protein 1 (LMP1), a member of tumor necrosis factor receptor (TNFR), is 
involved in NF-Kβ activation leading to an overexpression of antiapoptotic molecules and 
inflammatory cytokines (11). As well as LMP1 another member of TNFR is CD30 that is 
consistently detected on HL/RS cells. Since 1989 ELISA assay revealed that sCD30 is present at 
a very low levels in serum obtained from healthy donors, while increasing serum sCD30 has been 
observed in several conditions including HL (12) (13). Stimulation of CD30 with its ligand 
CD30L can induces pleiotropic effects including proliferation and cytokine secretion (14). Mir et 
al. suggested that a constitutive activation of NF-Kβ signalling in HL cell lines could lead to 
impaired sensitivity to CD30-mediated pro-apoptotic signalling (15). CD30 is another substrate 
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of ADAM10 protease, its extracellular domain can be cleaved and a soluble form (sCD30) is 
released. In particular, shedding of CD30 blocks the interaction between specific antibodies anti-
CD30 like Brentuximab-Vedotin, giving a further advantage to the tumor cells (16) (17). A 
recently identified mechanism of immune evasion is the inhibitory molecule programmed death-
1 (PD-1) and its ligand PD-L (18). In HL, PD-L is overexpressed both by malignant and 
surrounding cells and in thus depress the adaptive immune system in a process called “T-cell 
exhaustion”. In addition, PD-L is overexpressed by LMP1, which mimics CD40 signalling, and 
this highlight how these mechanisms are correlated to each other. 
Macrophages are another class of cells abundant in HL microenvironment. Indeed, exposure to 
soluble factors such as IL-4 and 13, produced by HL cells, leads to polarization of macrophages 
to the M2 phenotype, which suppresses cytotoxic T cell activity, facilitating tumor immune escape 
(19).  
 
Mesenchymal Stromal Cell and HL cells interaction 
All the cells described above reside in a complex microenvironment where interactions occur with 
the extracellular matrix (ECM), mainly composed by collagen, fibronectin, and laminin. Here 
MSC play a key role defining tissue architecture and monitoring tissue homeostasis. In addition, 
MSC secreted trophic factors are capable to promote tissue repair and immune modulation. MSC 
are responsible for the production of both components of ECM and enzymes that can modify ECM 
structure. For example, healthy fibroblast express low levels of activation protein (FAP) but 
expression increases during wound healing, osteoarthritis and in other pathological conditions 
(20). However, FAP is expressed by several tumor cells and thus it is difficult to distinguish the 
contribution of MSC from that of tumor cells. It is well known that there is not a single specific 
marker to identify MSC, but transglutaminase II (TGII) can be used to mark MSC by 
immunohistochemistry and cytofluorimetry (21). TGII is involved in many biological processes 
in cancer, such as tumor cell proliferation and apoptosis (22).  
Previous reports have found that MSC can alter the function of immune cells with both cell-to-
cell contact and the secretion of soluble cytokines. MSC express some counter-ligands for 
lymphocyte receptors involved in lymphocyte-MSC interaction (23) (19). In particular, the 
response of B cells to MSC is closely associated to the microenvironment. When MSC are co-
cultured with B cells in 2D in vitro conditions, they regulate immunoglobulin secretion, apoptosis, 
proliferation, plasma cell differentiation and chemotaxis of B cells (24) (8). 
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Interestingly, MSC also express matrix metalloprotease (MMP) and some members of a 
disintegrin and metalloprotease (ADAMs) family, both involved in cell development and 
migration (25). In particular, MSC release ADAMs both in exosomes and microvesicles; in this 
way ADAMs, released in the milieu, can cleave its ligands, such as CD30 on HL/RS membrane, 
preventing the recognition of an anti-CD30 antibody already used in clinical treatment (26). It 
should be noted that MSC also express stress molecules like NKG2DL that can be shed by 
ADAM10 and interfere with NKG2D during immune response (27). Taken together, this evidence 
indicates that MSC are involved in all tumor processes (28) (29) and they can contribute to 
determine an immune suppressive microenvironment also through ADAMs activity. For this 
reason, we focused our attention on a specific class of enzymes: ADAMs. 
 
Metalloproteases in cancer: the double blade of ADAMs 
Metalloproteases are proteolytic enzymes defined by the presence of a Zn2+ ion at the catalytic 
site which is important in different biological processes, from cell proliferation and differentiation 
to physio- and pathological processes, including cancer progression. As proteolytic enzymes, they 
catalyse the cleavage of substrates, such as growth factors, making them available to cells; on the 
other hand, degradation of ECM allows cells to move through the tissues more easily. Based on 
the mechanism involved, we can identify two metalloprotease families: MMPs and ADAMs (30) 
(25). MMPs are able to degrade the ECM while ADAMs are the major proteinase family that 
mediates the cleavage of several substrate thanks to their proteolytic ectodomain, a process called 
“shedding”. In particular, ADAMs are able to shed various cell surface proteins such as growth 
factors, receptors and their ligands, cytokines, and cell adhesion. The proteolytic event seems to 
be an important step because it (i) releases an intracellular protein domain, which could act like a 
signal transduction molecule, and (ii) the soluble domain can act as an extracellular signal 
preventing the functionality of several receptors involved in the immune response.  
Twenty ADAMs have been described in the human genome (31) but only 12 of these human 
ADAMs genes encode proteins that express the typical metalloprotease Zn-binding active site. It 
has been reported that ADAM9, 10 and ADAM 17 are active in several solid tumours and in 
haematological malignancies such us human myeloid leukaemia, myeloma, mantle cell 
lymphoma (MCL) and Hodgkin lymphoma (HL). ADAM10 was recently found to be one of the 
enzymes responsible of TNFα cleavage, which is one of the activators of NF-kB in MCL. In 
addition, ADAM10 promotes cell-cycle progression and increased cell growth with the 
modulation of cyclin D1 and TNFα/NF-kB signalling pathway (32). Since overexpression of 
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ADAM10 correlates with parameters of tumor progression, ADAMs have been proposed as both 
biomarkers and therapeutic targets in cancer. For this reason, ADAM10 inhibitors with anti-tumor 
effects have been developed. In particular, HL is characterized by an overexpression of ADAM10, 
and specific ADAM10 inhibitors have thus been proposed. Recently, (33) two ADAM10 specific 
inhibitors, LT4 and MN8, have been synthesized [11]. ADAM10 promotes an 
immunosuppressive microenvironment through an increased release of natural killer group-2 
ligands (NKG2DL), which are involved in an impaired immune response against tumor cells in 
HL (34). NKG2DLs are present at low levels also in normal cells but they can be induced in stress 
conditions, including cancer progression. LT4 and MN8 blocked the shedding of NKG2DL in the 
HL cell lines L540 and L428 that, in turn, developed increased sensitivity to NKG2D mediated 
killing (4). All the inhibitors were also able to reduce the shedding of TNFα, a cytokine described 
as a growth factors for lymphoma cells (35). 
In addition, several studies have reported the presence of ADAM10 released by HL cells and 
lymph node stromal cells in extracellular vehicles (EVs). Tosetti et al. reported that ADAM10 
inhibitor treatment restores normal membrane CD30 levels, which rescues the sensitivity to anti-
CD30 therapeutic monoclonal antibodies such as Iratumumab and Brentuximab-Vedotin, used in 
HL. The mechanism by which ADAM10 expression is modulated could be cell-type specific. 
Since ADAM10 expression is observed in both lymphocytes and stromal cells of patients, we 
have chosen to work with co-culture of these cells to investigate if metalloprotease inhibitors can 
contribute to reduce the invasive or metastatic capacity of the tumour. In particular, ADAM10 
may represents key targets for selective inhibitor in novel therapeutic schemes in order to reduce 
immune escape of malignant cells during the course of cancer therapy. 
 
Therapeutic treatment for Hodgkin’s lymphoma 
HL is a B-cell lymphoma that affects 20-40 year old people with a second incidence peak in 
subjects 55 years of age and is the most common lymphoma in adolescents between 15 and 19 
years of age. HL was one of first oncological pathologies to be treated by chemotherapy and 
radiotherapy. However, these therapies are accompanied by high toxicity and side effects; for 
example, the risk of coronary heart disease in HL has been shown to be related to the dose of 
radiotherapy. Infertility, pulmonary disfunction and diabetes are all consequences of long-term 
HL treatment, beside cytopenia and immunosuppression. It is clear that this topic needs a new and 
viable technique to improve the lives of patients (36) (37) (38). 
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Based on what is known on the physio-pathology of HL, several studies have been performed on 
the different patterns of tumor cells; from the escape of immune response, to the cycle progression 
up to JAK-STAT pathway. Monoclonal antibodies (mAbs) have emerged as a major focus for 
drug development for a cancer treatment; however, when used alone, they do not produce long-
lasting clinical benefits. For example, Nivolumab and Pembrolizumab are monoclonal antibodies 
that target PD-1, involved in the down-regulation of T cells in both priming phase and during the 
effector phase; these antibodies lead to the reactivation of T cell and T cell mediated tumor cell 
lysis. Interference with JAK-STAT pathway is another important aspect to be considered. 
Overactivation of this pathway has been linked to lymphoma, including HL. Ruvolitinib, a 
selective inhibitor of JAK1 e JAK2, may play useful role only in combination with other therapies. 
Targeting of lymphoma antigens are an alternative approach; in this contest CD30, is one of the 
most important candidates. CD30 is expressed on the surface of RS cells and is a member of the 
TNF receptor superfamily that affects cellular proliferation, survival and differentiation. CD30 is 
able to trigger apoptos and for this reason anti-CD30 antibodies construct with cytotoxic or 
radioimmunoconjugates have been developed (39). Nevertheless, these mAbs alone have not so 
far prove to be as effective as expected. 
In 2011 the Food and Drug Administration (FDA) approved Brentuximab-Vedotin as drug for the 
treatment of HL. Brentuximab-Vedotin is an antibody-drug conjugate consisting of the tubulin 
inhibitor monomethyl auristatin E (MMAE, Vedotin) linked to an anti-CD30 mAb (Brentuximab) 
(40). It acts through different mechanisms: (i) delivering MMAE inside the cell after antibody 
internalization, where MMAE binds to tubulin preventing its polymerization, (ii) a small fraction 
of MMAE diffuses out of the targeted cell exerting cytotoxic effects on surrounding cells in the 
tumor microenvironment and (iii) since Brentuximab-Vedotin recognize CD30 antigen, the 
binding could induce cell-cycle arrest and apoptosis (39). Apoptosis or programmed cell death is 
a form of cellular death characterized by distinct phases and activation of a cascade of protease 
called caspases. In vitro studies have elucidated two major apoptosis pathways: (i) a stress-
induced pathway mediated by cytochrome release from the mitochondria and subsequent 
activation of caspase 9 and (ii) death receptor-mediated pathway through the activation of caspase 
8. Both pathways induce apoptosis through the activation of caspase-3. HL RS cells highly express 
caspase-3 and other components of the TNFR-associated signal transduction machinery like 
CD30 receptor. Dukers and co-workers (41) (42), using a specific antibody against the activated, 
cleaved form of caspase-3, found that in vivo B cells lymphoma apoptosis always involves the 
activation of caspase-3. The absence of active caspase-3 negative cells indicates that, if expressed, 
8 
 
apoptosis inhibitory protein such as bcl-2 and inhibitor of apoptosis (IAP) express their influence 
by interference with this death-signalling cascade upstream from caspase-3 activation.  
However, we know that HL/RS cells are only a small fraction of the tumor mass and inflammatory 
cells and mesenchymal stromal cells can release chemokines that support the proliferation and 
survival of malignant RS cells. It seems clear how much the microenvironment is important in 
this contest and, based on this consideration, we planned to investigate whether ADAM10 
inhibitors in combination with Brentuximab-Vedotin can improve the therapeutic effect of the 
antibody drug conjugate on HL/RS cells (43). We hypothesize that (i) ADAM10 inhibitors can 
prevent CD30 shedding and TNFα release from HL/RS cells, (ii) since MSC are able to release 
ADAM10, anti-ADAM10 will reduce the reactivity of ADAM10 release from MSC thus restoring 
sensitivity to the anti-CD30 Brentuximab-Vedotin; (iii) in this way Vedotin, according with the 
literature, can act on tubulin and induce apoptosis through caspase-3 activation (44).  
 
Cell culture model: from in vitro 2D to 3D co-culture systems 
In the field of biomedicine research, it is important to find the right model to bridge the gap 
between in vitro findings and in vivo study. Standard preclinical screening procedures for 
anticancer agents involve target identification for the compound on immortalized cell lines 
cultured in a 2D (two-dimensional) monolayer. Once a target has been identified experiments can 
be performed with in vitro, mainly 2D culture, or in vivo with animal models. Both of these 
strategies suffer from relevant limitations. Animal models are very expensive and require a long 
set up time for each tumour. Experimental data from animal tests can be limited by interspecies 
differences that can be difficult to overcome; this fact, in conjunction with strong ethical concerns, 
is a strong incentive to develop alternative models to diminish animal testing. (45) (46) (47). 
2D cell monolayers have been used for a long time to predict drug effects or cell metabolism but 
do not resemble the complex interaction with all the other tissue cells and the cellular matrix 
(ECM) nor the complete tissue structure. A promising tissue engineering approach is the 
introduction of three-dimensional (3D) co-culture systems that can reflect cell behaviour and 
tissue architecture in healthy and tumour environments.  
One of the first 3D co-culture systems used for in vitro drug screening is the spheroid model (48). 
A powerful improvement of tumor spheroids over conventional 2D cell cultures is the presence 
of metabolic and proliferative gradients across their spherical geometry that can influence 
pharmacological efficacy. However, they can reach the size of 500µm and the core may often 
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undergo necrosis because nutrients and oxygen are limited in the spheroid centre and there is 
waste accumulation. Several technologies have been developed to create spheroids with uniform 
size, but this model does not consider the importance of tissue architecture (49). Tissue 
microenvironment deeply contributes to determine both cancer progression and outcome of anti-
cancer treatments; thus, newly designed in vitro models are being developed. Furthermore, there 
is increasing evidence that tumor development in humans is not fully reproducible in other 
animals, in particular when very complex models are designed (47). Thus, in the last years, the 
European Union Reference for Alternatives to Animal Testing (EURL ECVAM) has approved 
and validated several three-dimensional (3D) culture systems, including spheroids, as preclinical 
models to face and overcome these drawbacks (48). In addition, cell co-cultures that combine 
tumor with stromal cells in a 3D scaffold that reflect the native ECM composition can provide a 
biologically active microenvironment for cells to interact with (50) (45).  
 
Scope of thesis 
To study Hodgkin lymphoma, first of all we tried to obtain a suitable system resembling the lymph 
node microenvironment. In this context our first aim was to obtain an in vitro 3D model. Starting 
from the spheroid co-culture system, here we propose two different approaches based on (i) de-
cellularized lymph node matrix repopulatated with lymph node derived mesenchymal stromal 
cells (MSC) and HL cell lines and (ii) collagen scaffolds repopulated with MSC and HL cell lines. 
The second aim was to select the simplest and most reproducible model to evaluate the activity of 
the specific ADAM10 inhibitors LT4 and MN8 in HL, alone or in combination with Brentuximab-
Vedotin, to improve its therapeutic effect. The hypothesis is that LT4 and MN8 decrease the 
shedding of CD30 from HL lymphocyte surface, increasing the reactivity of Brentuximab and the 
cytotoxic effect of Vedotin. At the same time, since ADAM10 is released in exosome and 
microvesicles from stromal cells using anti-ADAM10 we aim to reduce shedding from the 
microenvironment, decreasing the tumor immune escape.  
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Materials and Methods 
Cell Cultures 
To evaluate the ADAM10 inhibitor activity we used the commercially available, stabilized L428 
HL cell lines, obtained from pleural effusion, and L540 cell lines obtained bone marrow of HL 
patients (DSMZ GmbH, Braunschweig, Germany). These cell lines, expressing both CD30 and 
the active form of ADAM10, were maintained in RPMI 1640 supplemented with 10% FBS, 2mM 
glutamine and 1% of penicillin/streptomycin (from now on we call medium B). Lymph node 
mesenchymal stromal cells (MSC) were cultured in α-MEM (GIBCO) supplemented with 2% of 
Chang medium, 10% FBS (GIBCO) 2mM glutamine, 1% of penicillin/streptomycin (from now 
on medium A). Stabilization of MSC cultures was performed as described (34). 
 
ADAM10 inhibitors 
Selective Adam 10 inhibitors LT4 and MN8 were synthesized and characterized as published (33). 
LT4 and MN8 are sulfonamido-based hydroxamate that inhibit ADAM10 by interacting with its 
catalytic domain and chelating the zinc ion, critical for both substrate binding and cleavage. LT4 
and MN8 were used on the co-culture composed by different HL cell lines with MSC at the 
concentration of 10 to 20µM (basic on the amount of the cells used) for 48, 72 and 96 hours. 
20µM of LT4 and MN8 were used in combination with the anti CD30 Brentuximab-Vedotin (Bre-
Ved, 20µg/ml to 2 µg/ml, obtained from the Pharmacy of the Ospedale Policlinico San Martino, 
Genoa, Italy) for the 3D collagen scaffolds experiment. 
 
Spheroid generation and culture 
Mixed spheroids of MSC and HL cells were prepared according to the method described with 
some modifications (51).  Briefly, 2x104 MSC were seeded in flat-bottom 96-well plates (Ultra-
Low attachment multi well plates, Corning®Costar®, NY, USA) with the appropriate culture 
medium A, as above. On day 4, after testing MSC viability through ATP content, measured on 
parallel samples, and assessing that the diameter of spheroids was of about 200μm, 1x105 HL cells 
were added to the cultures, and the medium replaced with fresh complete medium B, to promote 
HL cell growth over MSC. After 2 days, 10µM LT4 or MN8 were added and the cultures were 
kept at 37°C, in 5% CO2 humidified atmosphere for further 3 days. Generation of spheroids was 
monitored along time and proliferation and dimension (perimeter, area and volume) were 
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analyzed in each culture well 48h, 72h, or 96h after addition of LT4 or MN8. At least triplicates 
were analyzed for each culture condition and the number of spheroids analyzed as indicated in 
each figure (a minimum of 150 single spheroids for each independent experiment). 
 
De-cellularized matrix lymph node preparation 
Lymph nodes were obtained from the Unit of Pathology, IRCSS Policlinico San Martino, Genoa, 
under conventional diagnostic procedures and informed consent according to the institutional 
ethical committee approval (IRB approval 0026910/07, renewal 03/2009, and 14/09/15). 
Extracellular matrix from lymph nodes was prepared following a previously described protocol 
(52). Some experiments were performed using as scaffolds the Avitene microfibrillar collagen 
sponge (3mm thick, Davol Inc., Warwick, RI). 
 
3D co-cultures on LN decellularized matrix 
3D cell cultures were performed by suspending 6x105 MSC in 50µl of culture medium and seeding 
then onto a 50mg of fragment decellularized matrix, dipped in 1ml MSC culture medium A 1h 
before cell seeding. Samples were placed in a 24 well plate and kept at 37° in a 5% CO2 humidified 
incubator for 2h, then 1ml of complete  medium A was added and samples were cultured for 4 
days, with medium replacement on day 2. On day 5, 4x105 HL cells (either L428 or L540) were 
added to each ECM/MSC and cultured in medium B for further 2 days before addition of 
ADAM10 inhibitors. At this time, 10µM LT4 or MN8 were added to the culture for additional 
72h or 96h. Culture supernatants (SN) were recovered after 48h to determine TNFα or sCD30 
content and each 3D culture was embedded in paraffine for immunohistochemistry (IHC) and 
scanning electron microscopy (SEM). 
 
3D co-cultures on collagen scaffold 
First of all, we tested the capacity of MSC and L540 or L428 cells to grow inside the collagen 
scaffold. 24 well plates were coated with 1% sterile agarose and dried for 1 hour under hood. 
Sterile sheets of Avitene scaffold were cut whit sterile biopsy punches (Kia Medical, Japan) into 
5mm (3mm thick) fragments and then moved onto the agarose-coated plates. 
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MSC cells were grown in 75 T flask whit medium A until sub-confluence monolayer was formed, 
while HL cell lines (L540 and L428) were cultured in medium B. MSC were detached from the 
flask with Trypsin-EDTA (Euroclone) and 2x105 cells were suspended in 30µl of culture medium 
A and seeded into Avitene scaffolds. L540 and L428 were seeded at the concentration of 4x105 
in other scaffolds with the same procedure but in medium B. Samples were kept at 37° in 5% CO2 
humidified incubator for 2h; then 1ml of complete medium A and medium B was added 
respectively to MSC and HL cells and samples were cultured for 96h, replacing medium every 2 
days. Culture supernatants were recovered at different time points (24 to 96h) to analyse glucose 
consumption at different time. 
Sequential seeding was performed by suspending 2x105 MSC in 30µl of culture medium A and 
seeding on Avitene scaffold. Samples were kept for 2 hours at 37°C in a 5% CO2 humidified 
incubator, then 1 ml of complete medium A was added. Fresh cells medium was replaced after 48 
hours, then the samples were further cultured for 48 hours (4 days from time 0). After 48h, HL 
cells (either L428 or L540) were added to the scaffold. Briefly, 4x105 HL cells were suspended in 
30 µl of medium B and seeded onto the scaffold already repopulated with MSC. Samples were 
kept for 2 hours at 37°C in a 5% CO2 humidified incubator, then 1 ml of medium B was added to 
the scaffold and cultured for other 48 more hours.  
Mixture (Mix) seeding was performed by suspending both 2x105  MSC and 4x105 RS cells in 30µl 
of medium A and sowing onto the scaffold. After 2h at 37°C in a 5% CO2 humidified incubator, 
medium A was added. 48 hours later medium A was replaced with medium A+ medium B (1:1), 
and cells grew for further 48h. In both, sequential and mix seeding conditions, culture medium 
was recovered after 48, 72h and 96h to determine glucose consumption at different time point. 
 
Images and measurement of spheroid size 
Cell cultures were analyzed with Olympus IX70 bright field inverted microscope equipped with 
a CCD camera (ORCA-ER, C4742-80-12AG, Hamamatsu, Japan), associated to the CellSens 
software (version 1.12, Olympus, Tokyo, Japan). Images were taken with 10x objective NA 0.30 
or 20x objective NA 0.40 (100x or 200x magnification). After calibration of the plate, a grid 
corresponding to each well was created and analyzed; at least five focal points were taken for each 
well of interest to obtain optimal images to be measured. Images of the entire well were then taken 
through an automated x-y axis motorized table SCAN IM 120x100-2mm (Marzhauser Wetzlar 
GmBH, 35579 Wetzlar, Germany). Spheroids were measured by applying the “Count and 
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Measure” tool of the CellSens software, after creating circular regions of interest (ROI) that 
represented the spheroid perimeter. Data were then transferred to GraphPad Prism software 
(version 5.03) for subsequent statistical analysis and data plotting. To avoid counting and 
measuring very small spheroids or single cells or small cell/debris aggregates, only spheroids with 
a diameter greater than 50μm were selected. 
 
Scanning Electron Microscopy of decellularized LN matrix and collagen scaffolds 
Repopulated LN matrix fragments or collagen scaffolds were embedded in paraffin blocks and 
serially cut as 10µm thick sections using a Leica microtome. Sections were first deparaffinazed 
using xylene and then rehydrated in decreasing concentrations of ethanol solutions. Samples slices 
were collected on a glass coverslip, mounted on aluminium stubs and sputter-coated for 3 minutes 
with gold. Morphology and ultrastructure of samples were investigated by Scanning Electron 
Microscopy (SEM) performed on a Hitachi TM 3000 Benchtop SEM instrument operating at 
15Kv acceleration voltage.   
 
ATP content in spheroid co-cultures 
 
ATP content was determined using the CellTiter-Glo® Luminescent Cell Viability Kit (Promega 
Italia Srl, Milan, Italy) following manufacturer’s instruction using the luciferase reaction 
consisting in mono-oxygenation of luciferin catalyzed by luciferase in the presence of Mg2+, ATP 
and molecular oxygen. Luminescence was detected with the VICTORX5 multilabel plate reader 
(Perkin Elmer, Milan, Italy) expressed as relative light units (RLU); in some instances, the RLU 
were converted in μM of ATP according to a standard curve. 
 
Glucose Assay in co-culture medium 
The amount of glucose in cells medium was evaluated thought Megazyme D-Glucose Kit (K-
GLUC, Megazyme). Briefly, medium from cells co-culture was collected and centrifuged in order 
to pellet cell debris.10µl of medium was transferred in 96 well and 290 µl of GOPOD Reagent 
was added. Plate was incubated at 40°C for 20 min and absorbance was read in Victor 




TNFα and sCD30 ELISA 
Supernatants (SN) from cell cultures untreated (control condition) and treated with ADAM10 
inhibitors LT4, MN8 and LT4+Bre-Ved, MN8+Bre-Ved were collected at 72 and 96 hours. CD30 
shedding was measured by the specific ELISA detection kit (Human CD30 Picokine ELISA Kit 
from Boster Bio, TebuBio, Milan, Italy) and read at OD 450 nm. Results are expressed as pg/ml 
and referred to a standard curve obtained with the standard CD30 contained in the specific kit. 
TNFα was measured after treat SN for 1 hour with 1N HCl followed by 1N NaOH with a TNFα 




3D co-cultures were fixed in Histochoice (Amresco, Solon, OH) overnight at 4°C. After 
dehydration in increasing concentrations of ethanol solutions, samples were clarified in xylene 
and paraffin embedded. For each scaffold 5 µm serial sections were cut up to a depth of about 50 
µm, dried over night at 37°C. Some sections were used to performed hematoxylin eosin staining. 
Briefly, slides were rehydrated by decreasing concentration of ethanol solutions and coloured by 
hematoxylin; wash in distilled water and then coloured with eosin; finally covered with Eukitt 
mounting medium (Bio optica). 
 
Immunohistochemistry (IHC) and Immunofluorescence (IF) 
For IHC and IF at least three glasses were used. In each glass three 5 µm sections were collected 
and cut at a distance of 15 µm, in order to avoid repeated analyses on the same cells. 
IHC was performed after peroxy-block (Novex, Life Technologies) to quench endogenous 
peroxidase, followed by ultra-block reagent (Ultravision Detection System, Bio Optica, Milan, 
Italy). Mouse anti-human CD30 Ber-H2 (1:10, Ventana), polyclonal rabbit anti-human TGII 
(1:100, Thermo Scientific) and rabbit anti-human caspase-3 (1:1000, Cell Signaling) antibodies 
were used. Biotinylated goat anti-rabbit and anti-mouse (Biot-Gam, Bio Optica) antibodies were 
then added, followed by HRP-conjugated avidin (HRP-Av, Thermo Scientific) and the reaction 
developed using 3,3’-diaminobenzidine (DAB,Sigma) as chromogen. Slide were counterstained 
with hematoxylin, cover-slipped with Eukitt (Bio Optica) and analysed under Leica DM MB2 
microscope equipped with Olympus DP70 with a 20x or 40x objective. 
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IF was performed using the automated stainer BOND RXm (Leica): slides were covered by Bond 
Universal Covertiles (Leica Biosystems) and placed into the Bond RXm instrument. All 
subsequent steps were performed according to the manufacturer’s instructions (Leica Biosystem) 
in the following order: (1) deparaffinization with Bond Dewax Solution (Leica Biosystem) at 
72°C for 30 minutes; (2) incubation with a cocktail of our two primary mouse anti-human CD30 
(1:2, Ventana) and rabbit anti-human Ki67 (1:5, Ventana) at 35°C; (3) washing with Bond Wash 
for 4 minutes; (4) incubating with a cocktail of anti-mouse Alexa fluor-594 (1:1000) and anti-
rabbit Alexa fluor-488 (1:1000) at 37°C for 30 minutes; (5) washing with Bond Wash and distilled 
water for 4 minutes. Slides were then counterstained with DAPI at 5µg/ml in PBS for 30 seconds 
and mounted with FluoromountTM (Diagnostic Biosystem). 
 
Scanning and computerized imaging 
IHC caspase-3 images were scanned by ApertioAT2 scanner and pictures were analysed with the 
Genie pattern recognition software tool (Leica Biosystems) to identify nuclei and caspase-3 
positive cells. The IF staining obtained as described above, were analysed with the Aperio VERSA 
Digital Pathology Scanner (Leica Biosystem). Images were captured at 20x enlargement in three 
channels: DAPI for cell nuclei, CD30 Alexa fluor-594 for membrane stain and Ki67 Alexa fluor-
488 to identify proliferating cells. Following the manufacturer’s instruction, we set the score 
classification criteria for every class within the algorithm settings. Image data were then analysed 
with Aperio Cellular IF Algorithm (Leica Biosystem) that allowed to classify cells in two different 
classes: class 1 KI67+ and CD30+ cells and class 2 only CD30+ cells, which allowed to assess 




Results and Discussions 
ADAM10 inhibitors LT4 and MN8 activity on spheroid co-cultures 
To test ADAM10 inhibitors on HL cells, 3D cell culture models were used: mixed spheroids of 
MSC and L540 or L428 were treated with 10µM LT4 or MN8, and cultures were kept at at 37°C 
for 48h, 72h or 96h.  
Spheroid dimensions (fig.1, panel C) were analyzed in each cell culture as described in Materials 
and Methods. Of note, both LT4 and MN8 significantly reduced the size of mixed spheroids, and 
this effect was particularly evident after 96h. In addition, LT4 and MN8 reduced the ATP 
production in the spheroids in particular at 96h, while there was no effect on spheroids made by 
only MSC (data no shown). 
 
Figure 1. In A confocal microscopy of MSC and L540 mixed spheroids staining with anti-CD30; in B the ATP content in spheroids  
treated with LT4 and MN8 for 48, 72h and 96h  was decrease compared with the control (none); in C is reported spheroids’ area 
reduction. The spheroids size decreases especially after 96h after treatment; *p<0.01 and **p<0.001 vs CTR. 
 
ADAM10 inhibitors LT4 and MN8 reduce CD30 and TNFα secretion by HL cells on de-
cellularized lymph node matrix and 3D scaffold 
Matrix scaffolds from LN were seeded in 24 well plates in duplicate and repopulated with MSC 
(5x105) for 4 days and (4x105 ) L428 for further 3 days as described in Materials and Methods. 
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Then, 10μM LT4 or MN8 were added to the the cultures and 400μl/well were harvested at 96h 
for TNFα and sCD30 measurement by ELISA. TNFα has been shown to be produced by a 
different tumour cells, including B cell lymphomas, and acts as an autocrine growth factor while 
CD30 is highly express on RS cells (54). Repopulated decellurarized matrices were embedded in 
paraffine and IHC for CD30, to identify HL cells, and TGII, to stain MSC, was performed. As 
visible from fig. 2, decellurarized matrix was repopulated with HL cells (panel A; CD30) and 
MSC (panel B; TGII) and also in this 3D system, as observed in mixed spheroids, the inhibitors 
reduced the shedding of TNFα (panel C) and sCD30 (panel D), with a gradient of efficacy resultin 
in LT4>MN8. 
 
However, decellularized matrices were difficult to obtain, were difficult to standardize, in terms 
of scaffold size and shape, and could barely substain a single experiment in triplicate (i.e. three 
3D replicates with MSC co-cultered with one HL cell line only). As an alternative, 3D 
commercially available scaffolds could represent a good choice since they correlate well to the in 
vivo situation, they were standardized and compatible with imaging techniques. In this thesis we 
would reproduce a lymph node using typical tissue engineering approaches through the 
combination of 3D co-culture and scaffold. Thus we decided to adopt commercial sponges made 
of microfibrillar collagen (Avitene Sponges, see Materials and Methods), already used as 
Figure 2. In A IHC for CD30 in de-cellularized matrix lymph node repopulate with MSC and L428 cells; in B IHC for TGII show MSC 
scaffold repopulation; in C and D ADAM10 inhibitors decrease respectively TNFα and CD30 secretion in 3D co-culture model 
made  by de-cellularized lymph node with MSC and L428 cells.*p<0.005 vs CTR; ** p<0.001 vs CTR. 
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hemostats in surgery. Thanks to the collaboration with Gena  CNR Institute, we were able to 
perform a SEM characherization. Figure 3B  shows the sponge, analyzed by SEM, compared to a 
de-cellularized LN matrix (fig.3A). The 3D structure of the sponge is similar to that of the de-
cellularized matrix with a network of round shaped niches of approximately 10-50µM of diameter, 
defined by collagen fibre bundles 
To evaluate if the scaffold was suitable for the growth of our cells models, we first seeded MSC 
and L540 or L428 alone into the scaffold. Avitene sponges were cut in 5x5x3 (w x l x h) mm 
scaffolds; 2x105 MSC or 4x105 L540 (or L428) were seeded and kept in culture for 96h.  
Figure 1. in A SEM of de-cellularized lymph node matrix; in B SEM of Avitene scaffold 
Figure 4. In A MSC on Avitene scaffold (HE staining, upper panel) and glucose concentration in the medium at the 
indicated time points (lower panel); B L428 on the scaffold (HE staining, upper panel) and glucose concentration 
(lower panel) and in C sequential seeding of MSC and L428 on the scaffold for 96h (HE, upper panel) and glucose 
concentration (lower Panel) 
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As we can see in figure 4, both MSC (panel A) and HL cells (panel B) were able to colonize the 
scaffold (panel A: hematoxylin-eosin staining and glucose consumption during time (lower 
graphs). We can observe that scaffold architecture is much better preserved in panel A than in 
panel B. In fact, MSC are responsible for matrix production, which allow to preserve the scaffold 
architecture. L428 alone (panel B) colonized the scaffold but the internal structure was appeared 
much more fragmented compared with MSC (panel A). However, glucose consumption (lower 
graphs in panels A and B) indicates that both MSC and L428 were able to grow onto the scaffold. 
In order to obtain a suitable 3D in vitro model of HL and test ADAM10 inhibitor we proceeded 
with the sequential seeding as we did for the de-cellularized lymph node matrix (see materials and 
methods). Panel C reports the hematoxylin eosin staining: MSC and L428 were able to grow 
toghether on the scaffold while preserving the microarchitecture of the material; glucose 
consumption is reported in the lower graph of panel C, which shows a decrese in glucose 
concentration in the medium over time indicating that cells were metabolically active. Once 
confirmed the repopulation of the scaffolds through hematoxylin eosin staining and consumption 
of glucose, we proceded to evaluate ADAM10 inhibitor activity in the culture. 20µM of LT4 or 
MN8 were added to the cultures and 400μl/well were harvested at 72h and 96h for TNFα and 
sCD30 measurement. As observed for  spheroids and LN de-cellularized matrices, LT4 and MN8 
reduced the shedding of sCD30 and TNFα (fig. 5) by both L428 (fig. 5A) and L540 (fig.5B) HL 
cells.  
 
Figure 5. In A: ADAM inhibitors in MSC+L428 co-culture decrease the secretion of CD30 and TNFα; in B: MSC+L540. ** p<0.005 
vs CTR; *** p<0.001 vs CTR 
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The anti-sheddase effect was evident by 72h for L428 (fig. 5 panel A) and at 96h for L540 cells 
(fig. 5 panel B). These data suggest that the experimental model was feasible and reproducible. 
At the end of the culture, in order to characterize the homing of  MSC and HL cells into the 
scaffold after 96h of culture, immunohystochemistry (IHC)  was performed. IHC was performed 
using the automated stainer Bond RXm (Leica) in collaboration with the unit of Molecular 
Oncology and Angiogenesis from IRCSS Ospedale Policlinico San Martino, Genoa. To identify 
MSC and HL cells, the anti-TGII and the anti-CD30 antibodies were used, respectively. Scaffolds 
were efficiently repopulated by MSC (TGII positive, fig. 6A) and L428 cells (CD30 positive cells, 
fig. 6B). 
 
Figure 6. IHC of Avitene scaffold repopulates by sequential seeding with MSC and L428 cells. In A TGII shows MSC colonization 
while the insert represents the whole repopulated scaffold; in B the inset shows the negative control while the magnifiers 
identify CD30+ L428 cells on the scaffold 
 
LT4 and MN8 inhibit HL cell proliferation in the 3D repopulated scaffolds 
In a further series of experiments, we measured the effects of ADAM10 inhibitors on the 
proliferation of HL cells seeded in the 3D Avitene scaffold. Avitene sponges repopulated with 
MSC and L428 or L540 cells, as above, were exposed to 20µM LT4 or MN8 or in combination 
with Bre-Ved (20µg/ml) for 72h and 96h. Then, the 3D co-cultures were paraffin embedded and 
5µm sections were prepared. IF for CD30 and Ki67, as a marker of cell cycle, was performed to 
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identify proliferating L540 or L428 inside the scaffold: the anti-CD30 mAb, followed by 
Alexafluor594-conjugated GAM, identifies RS cells (red membrane staining) and the anti-Ki67 
polyclonal antibody, followed by Alexafluor488-conjugated anti-rabbit antiserum, identifies 
proliferating cells, while DAPI staining marks all cell nuclei (blue). 
Slides were scanned with Aperio VERSA Slide Scanning and images were analyzed by 
ImageScope software using the Aperio Cellular IF Algorithm (Leica Biosystems). This software 
allows to discriminate different signals on the same cells by setting several parameters such as 
nucleus identification, cytoplasmic counterstain, dyes input parameters and in which cellular 
component they should be located in. One of the most important parameters is the scoring 
classification which categorizes cells in different classes.  In this way the operator can create a 
mask that can automatically analyze the images. Our aim was to create a mask able to discriminate 
between CD30+KI67- (non proliferative HL cells) as class 1 and CD30+KI67+ (proliferative HL 
cells) as class 2. According to the manufacturer’s instruction and with different experiments, we 
set all the dyes threshold and created the macro. We analyzed at least three slides for condition 
using the same macro and the same parameters and calculated the amount of proliferating L540 
or L428 cell over the total HL cell number in the scaffold. Figure 7 shows representative images 
of repopulated scaffolds, cultured for 96h captured at 20x magnification.  
 
Figure 7. IF of Avitene scaffold with CD30+ HL cells (red), Ki67+ (green) as proliferating marker and nuclei (blue) 





When the software analyzes the pictures, it returns a quantification, in terms of cell numbers, wich 
can be used to quantify the cells of interest. As shown in fig 8, the number of CD30+Ki67+ HL 
cells was generally lower in the presence of LT4 and MN8; the effect of LT4 was evident at 72h, 
while MN8 inhibition was maintained also at 96h. L540 was less sensitive to the inhibition exerted 
by the two ADAM10 blockers (fig.8 panel A); nevertheless, the reduction of proliferating HL 
cells for MN8 was significant at 96h (fig.8 right panel). We got significative results also with 
L428 HL cells (fig.8 panel B). The effects of ADAM10 inhibitors were evident at 72h but even at 
96h were visible. 
 
Figure 8. Quantification of CD30+ki67+/total lymphocytes on the scaffold after ADAM10 inhibitors treatment. In A is reported 
the quantification about L540 cells, the effect of MN8 is visible both 72 and 96h; in B ADAM10 inhibitors effect on L428 
proliferation with fewer proliferating cells at 72 and 96h after the treatment. * p<0.05 vs control; ** p<0.005 vs control 
 
Sequential seeding and Ki67 IF do not meet our needs: mix seeding and caspase-3 IHC evaluation  
Avitene scaffold represents a suitable 3D experimental model. However, with the sequential 
seeding the scaffolds seems to be colonized mostly in the outer portion. To better reproduce the 
cellularity of a LN node environment we had to improve the seeding technique. For this reason, 
we mixed together MSC and HL cells before seeding the mixture (mix) onto the scaffold. To 
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compare sequential seeding versus mixture we performed hematoxylin eosin staining and then IF 
for CD30- Ki67.  
 
Figure 9.In A upper panel HE of MSC and L428 by sequential seeding; in lower panel IF for CD30 in red, Ki67 in green and in blue 
nucleus; in panel B upper picture HE of MSC and L428 by mixture seeding and in the lower panel IF. With mixture seeding 
scaffold was repopulated also in inner areas  
 
The results are shown in figure 9. Comparing panel A and B, scaffolds in both conditions were 
repopulated and the architecture was maintained. However, as shown in the IF image of panel B, 
HL cells were identified not only in the outer region but also in the center of the scaffold. In 
contrast, as we can see in A (lower panel) with the sequential seeding HL cells were observed 
mainly in the outer region. Based on these findings, we chose to work with the mixture seeding 
that allows us a better representative repopulation.   
We tried then to verify the hypothesis that the combination of ADAM10 inhibitors with Bre-Ved 
could increase the number of non-proliferating lymphocytes. To this aim, Ki67 turned out to be 
inappropriate to measure proliferating cells: indeed, since Ki67 is detectable in the nucleus not 
only in the mitotic phase but also in the interphase (55), KI67 positive cells may be scored as 
proliferating although actually being in other cell cycle phases. For this reason, we chose to 




Unfortunately, we could not use IF to evaluate the number of positive caspase-3 HL cells because 
of aspecific fluorescent signal released by the scaffold that clouded the staining with the anti-
caspase-3 antibody. Thus, we analyzed caspase-3 activation in IHC as described in Materials and 
Methods.  
 
Caspase-3 activation in HL cells upon Bre-Ved and ADAM10 inhibitors treatment 
 
In the previous paragraph we highlighted that ADAM10 inhibitors reduced CD30 and TNFα 
shedding in our experimental model. Now we focus on the apoptotic process. During the last 
experiment we used Brentuximab, an anti-CD30 antibody, conjugated with Vedotin, a drug that 
binds cytoskeletal tubulin, alone or in combination with anti-ADAM10 inhibitors. The aim was 
to enhance the interaction between CD30 on HL cells and Bre-Ved in order to trigger the apoptosis 
response. In our 3D model we tested two different concentrations of Bre-Ved (i) 20µg/ml and (ii) 
2µg/ml in order to evaluate a possible synergistic effect between Bre-Ved with LT4 and MN8. 
We were able to detect caspase-3 positive cells on the scaffold through IHC as we can see from 
figure 10, panel B (treated) vs panel A(untreated). Then, the Genie software was used to calculate 
the amount of caspase-3 positive cells in the scaffold. In figure 10, panel C reports the percentage 
of positive L428 cells in all the conditions while in panel D reports L540 cells response to the 
treatment.  
Bre-Ved at 20µg/ml increased the percentage of caspase-3 positive L428 cells as well as with LT4 
and MN8 but a small synergistic effect was observed with Bre-Ved 20 µg/ml+ LT4 or MN8. With 
regard to the concentration Bre-Ved 2µg/ml, we could not observe  significative results in terms 
of increased caspase-3 positive cell.  
Different results were obtained with the L540 cell line; as we can see from figure10, panel D, 
caspase-3 positive cells increased upon treatment with either Bre-Ved 20µg/ml or 2µg/ml. 
However, when Bre-Ved was used at higher concentration, no addictional effect with LT4 and 
MN8 was been observed. Interestingly, the combination of Bre-Ved 2µg/ml plus LT4 and MN8 
increased the pertentage of caspase-3 positive L540 cells. These data suggest that further 
investigations are needed to elucidate the possible synergistic effect of ADAM10 inhibitors and 





Figure 10. In A caspase-3 IHC of CTR (no treated) scaffold vs in B treated Brentuximab-Vedotin; in C quantification of positive 
caspase-3 cells through Genie analysis. Brentuximab-Vedotin in combination or not with ADAM10 inhibitors increase the 
amount of positive caspase-3 cells. C: **p<0.0005 and *p<0.05 vs CTR; D: **p<0.05 vs BtxVed and *p<0.05 vs CTR 
 
Conclusions 
Numerous signal pathways deregulated metabolic activity in HL cells. The activation of these 
pathways is mediated by the interaction of HL/RS cells with other cells in their microenvironment. 
This microenvironment probably promotes the survival of HL/RS cells and helps them to escape 
immune surveillance. Considering the numerous cellular interactions, every single molecule 
involved may potentially offer novel strategies for targeted therapies, for instance by specific 
inhibition of signalling pathways. However, it is also very difficult to test new drugs since there 
is not a suitable published experimental model to work with. For this reason, in order to improve 
the therapeutic efficacy of drugs already approved for the treatment of Hodgkin’s lymphoma such 
us Brentuximab-Vedotin, in this work we suggest different, suitable and low-cost in vitro 3D 
models of HL: mixed spheroids made of MSC and HL cells and collagen scaffold repopulated 
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both with MSC and HL cells; de-cellularized matrices were excluded since the experiments were 
not easy to reproduce. Using specific ADAM10 inhibitors, LT4 and MN8, we restored the bio-
availability of CD30 in HL cells in order to increase the recognition by Brentuximab and 
determine the activation of apoptotic pathway through Vedotin. 
In these 3D systems we found that: (i) LT4 and MN8 reduce HL cells metabolism in spheroids, 
i.e. ATP production related to proliferation; (ii) the two inhibitors lead to mixed spheroids size 
reduction and inhibition of sCD30 and TNFα shedding; (iii) both effects are also evident in LN 
matrices or collagen scaffolds repopulated with LN-MSC and HL cells.  
The spheroid 3D system, approved as a pre-clinical model (51), is reproducible, cheap and allows 
the processing of a large number of samples. Furthermore, MSC act as a round shaped core that 
HL cells can use as a scaffold, and that can be easily measured in size. In this system, LT4 and 
MN8 could efficiently exert their anti-sheddase activity, and also interfere with HL cell 
metabolism, as demonstrated by ATP variations. Another consequence of the inhibitor effect is the 
reduction in spheroid size, conceivably due to inhibited HL cell growth.  A third effect is the 
reduction of CD30 and TNFα shedding; lower amounts of TNFα should decrease proliferating 
signals delivered to lymphoma cells, while the down-regulation of CD30 shedding would 
maintain the expression of the molecule at the cell surface, enhancing the action of Bre-Ved. 
However, spheroids cannot reproduce the lymph node architecture that supports the activation of 
cell signaling pathways (56). For this reason, we moved to another system composed by 
decellularized matrix lymph node repopulate with MSC and HL cells and we tested the activity 
of the ADAM10 inhibitors LT4 and MN8. With this model we had results in line with the spheroid 
system. In particular, LT4 and MN8 were able to reduce ADAM10 sheddase activity on CD30 and 
TNFα. Of note, since the material is obtained from patients, a very long waiting time is required 
to reproduce the experiment. In addition, decellularized matrix were difficult to standardize in 
term of scaffold size and shape. Fortunately, several biomaterials can be used in order to resemble 
tissue architecture and optimize the 3D system. For this work we choose the microfibrillar 
collagen sponge Avitene, already used for hemostatic purposes in surgery. Thanks to the 
collaboration with the CNR of Genoa we studied our scaffold though scanning electron 
microscopy (SEM) and we observed that the architecture of these sponges was very similar to that 
of decellularized matrices obtained from lymph nodes, thus representing a good alternative to test 
ADAM10 inhibitors. Avitene scaffolds could be repopulated by MSC and HL cells; also in this 
experimental model, the anti-sheddase effect of LT4 and MN8 was documented using ELISA 
quantification of CD30 and TNFα in the supernatant at different time points and IF supporting 
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previous data obtained. Another aim was to study the activity of Brentuximab-Vedotin in 
combination with LT4 and MN8. Our hypothesis was to enhance the availability of CD30 thanks 
to the anti-sheddase LT4 - MN8 activity for Brentuximab and then, thanks to Vedotin activity, 
induce an apoptotic response in HL cells. Caspase-3 IHC shows that the percentage of caspase-3 
positive cells was higher in presence of Bre-Ved. In addition, a low concentration of Bre-Ved we 
can improve the synergistic effect with ADAM10 inhibitors and increase its apoptotic effect on 
HL cells. Since the synergistic effect was not observed on both the cell lines, more studies will be 
performed to highlight the effects of Bre-Ved+ ADAM10 inhibitors on different cells. 
In conclusion, we set up an experimental model that could represent a new promising tool to study 
HL in a 3D in vitro model reproducing the microarchitecture of the lymphoma matrix and useful 






1. Hodgkin lymphoma. Ralf Küppers, 1 Andreas Engert,2 and Martin-Leo Hansmann3. 2012, The Journal 
of CLinical Investigation, pp. 3439-3447. 
2. Hodgkin Disease and the Role of the Immune System. Alana A. Kennedy-Nasser, MD, Patrick Hanley, 
BS, and Catherine M. Bollard, MD. 2011, Pediatr Hematol Oncol, pp. 176–186. 
3. Serum Level of the Soluble Form of the CD30 Molecule Identifies Patients With Hodgkin’s Disease at 
High Risk of Unfavorable Outcome. Gianpaolo Nadali, Luisa Tavecchia, Elisabetta Zanolin, Valeria 
Bonfante, Simonetta Viviani, Edgarda Camerini, Pellegrino Musto, Nicola Di Renzo, Mario Carotenuto, 
Marco Chilosi,Mauro Krampera, and Giovanni Pizzolo. 1998, Blood. 
4. ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to 
NKG2D-mediated killing. Maria Raffaella Zocchi, Caterina Camodeca, Elisa Nuti, Armando Rossello, 
Roberta Venè, Francesca Tosetti, Irene Dapino, Delfina Costa, Alessandra Musso & Alessandro Poggi. 
2016, OncoImmunoligy. 
5. Genetic instability in Hodgkin’s lymphoma. D. Re, T. Zander, V. Diehl & J. Wolf. 2002, Annals of 
Oncology. 
6. Secretory pathways generating immunosuppressive NKG2D ligands. Aroa Baragaño Raneros, Beatriz 
Suarez-Álvarez and Carlos López-Larrea. 2014, OncoImmunology. 
7. How to exploit stress-related immunity against Hodgkin’s lymphoma. Zocchi, Alessandro Poggi and 
Maria Raffaella. 2013, OncoImmunology. 
8. Interaction between Mesenchymal Stem Cells and B-cells. Linxiao Fan, Chenxia Hu, Jiajia Chen, Panpan 
Cen, JieWang and Lanjuan Li. 2016, International Journal of Moleclar Sciences. 
9. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for 
immunotherapy. Houot, Marie de Charette and Roch. 2018, Haematologica. 
10. Expression levels of caspase-3 in EBV positive and negative Hodgkin Lymphoma patients. Al-Khazaali, 
Ibrahim Abdul-Majeed Altamemi and Ali Sabri. 2019, Annals of Tropical Medicine & Public Health. 
11. Frequent Expression of the Tumor Necrosis Factor Receptor–Associated Factor 1 in Latent Membrane 
Protein 1–Positive Posttransplant Lymphoproliferative Disease and HIV-Associated Lymphomas. PAUL G. 
MURRAY, PHD, LODE J. SWINNEN, MD,JOANNE R. FLAVELL, BSC, MARGARET V. RAGNI, MD,KARL R.N. 
BAUMFORTH, PHD, SIOBHAN M. TOOMEY,ALEXANDRA H. FILIPOVICH, MD, DEREK LOWE, PHD,CARRIE 
S. SCHNELL, BA, JEWEL JOHL, BA, MARGARET GULLEY, MD,LAWRENCE S. YOUNG. s.l. : HUMAN 
PATHOLOGY, 2001. 
12. Serum Level of the Soluble Form of the CD30 Molecule Identifies Patients With Hodgkin’s Disease at 
High Risk of Unfavorable Outcome. Gianpaolo Nadali, Luisa Tavecchia, Elisabetta Zanolin, Valeria 
Bonfante, Simonetta Viviani, Edgarda Camerini, Pellegrino Musto, Nicola Di Renzo, Mario Carotenuto, 
Marco Chilosi Mauro Krampera, and Giovanni Pizzolo. 1998, Blood. 
13. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease 
activity and clinical stage . G Pizzolo, F Vinante, M Chilosi, F Dallenbach, O Josimovic-Alasevic, T 
Diamantstein, H Stein. 1990, British Journal of Heamatology. 




15. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. S 
S Mir, B W Richter, C S Duckett. 2000, Blood. 
16. CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-
expressing bystander cells with Brentuximab-Vedotin, in vitro. Hinrich P. Hansen, Ahmad Trad, Maria 
Dams, Paola Zigrino, Marcia Moss, Maximilian Tator, Gisela Schön, Patricia C Grenzi, Daniel Bachurski, 
Bruno Aquino, Horst Dürkop, Katrin S Reiners, Michael von Bergwelt-Baildon1, Michael Hallek. 2016, 
Oncotarget. 
17. ADAM10 Inhibition of Human CD30 Shedding Increases Specificity of Targeted Immunotherapy In 
vitro. Dennis A. Eichenauer, Vijaya Lakshmi Simhadri, Elke Pogge von Strandmann, Dennis A. 
Eichenauer, Vijaya Lakshmi Simhadri, Elke Pogge von Strandmann, Paul Saftig, Stefan Rose-John, 
Andreas Engert, and Hinrich P. Hansen. 2007, Cancer Research. 
18. Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New 
Perspectives. Diego De Goycoechea, Gregoire Stalder, FilipeMartins, andMichel A. Duchosal. 2019, 
Journal of Oncology. 
19. Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets 
in Classical Hodgkin Lymphoma. Eleonora Calabretta 1, Francesco d’Amore 2 and Carmelo Carlo-Stella. 
2019, International Journal of Molecular Sciences. 
20. Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. 
Giuliani, Alessandro Poggi and Massimo. 2014, Vaccines. 
21. Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived 
mesenchymal stem cells. Heesang Song, Woochul Chang, Soyeon Lim, Hye-Sun Seo, Chi Young Shim, 
Sungha Park, Kyung-Jong Yoo, Byung-Soo Kim, Byoung-Hyun Min, Hakbae Lee, Yangsoo Jang, Namsik 
Chung, Ki-Chul Hwang. 2007, Stem Cells. 
22. Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth. H 
Tatsukawa, Y Furutani, K Hitomi and S Kojima and death. 2016, Cell Death and Disease. 
23. Generation of a synthetic lymphoid tissue–like organoid in mice. Watanabe, Sachiko Suematsu & 
Takeshi. 2004, Nature biotechnology. 
24. Human mesenchymal stem cells modulate B-cell functions . Anna Corcione 1, Federica Benvenuto, 
Elisa Ferretti, Debora Giunti, Valentina Cappiello, Francesco Cazzanti, Marco Risso, Francesca Gualandi, 
Giovanni Luigi Mancardi, Vito Pistoia, Antonio Uccelli. 2006, Blood. 
25. The “A Disintegrin And Metalloprotease” (ADAM) family of sheddases: Physiological and cellular 
functions. Karina Reiss, Paul Saftig. 2008, Seminars in Cell & Developmental Biology. 
26. How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment immunostimulant 
Rather Than immunosuppressive. Alessandro Poggi1, Serena Varesano and Maria Raffaella Zocchi. 2018, 
Frontiers of Immunity. 
27. Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. 
Giuliani, Alessandro Poggi and Massimo. 2016, Vaccines. 
28. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced 
chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Xu, S., et al. 2012, Stem Cells. 
29. Stress immunity in lymphomas: mesenchymal cells as a target of therapy . Alessandro Poggi, Maria 
Raffaella Zocchi. 2014, Frontiers in Bioscience. 
30 
 
30. Expression of Members of the Novel Membrane Linked Metalloproteinase Family ADAM in Cells 
Derived from a Range of Haematological Malignancies . E. Wu, P. I. Croucher, and N. McKie. 1997, 
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 
31. The evolution of ADAM gene family in eukaryotes . J.S.M.Souzaa, A.B.P.Lisboa, T.M.Santos, 
M.V.S.Andrade, V.B.SNeves, J.Teles-Souza, H.N.R.Jesus, T.G.Bezerra, V.G.O.Falcão, R.C.Oliveira, 
L.E.Del-Bem. 2020, Genomics. 
32. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Werb, Chieh 
Chang and Zena. 2001, Trends Cell Biology. 
33. Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM10) able to 
reduce the shedding of NKG2D ligands in Hodgkin’s lymphoma cell models. Caterina Camodeca, Elisa 
Nuti, Livia Tepshi, Silvia Boero, Tiziano Tuccinardi, Enrico. 2016, European Journal of Medicinal 
Chemistry. 
34. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands 
recognition in Hodgkin lymphomas. Maria Raffaella Zocchi, 1 Silvia Catellani, Paolo Canevali, Sara 
Tavella, Anna Garuti, Barbara Villaggio, Annalisa Zunino, Marco Gobbi, Giulio Fraternali-Orcioni, 
Annalisa Kunkl, Jean-Louis Ravetti, Silvia Boero, Alessandra Musso, and Alessandro Poggi. 2011, Blood. 
35. TNF-alpha in onset and progression of leukemia. Xiaoxi Zhou, Zhuoya Li, Jianfeng Zhou. s.l. : 
Experimental Hematology, 2016. 
36. Hodgkin lymphoma. Ralf Küppers, Andreas Engert, and Martin-Leo Hansmann. 2012, The Journal of 
Clinical Investigation. 
37. Hodgkin's disease: a tumor with disturbed immunological pathways. Hans-Jiirgen Grur, Antonio 
Pinto, Justus Duyster, Sibrand Poppema and Friedhelm Hermann. 1997, Immunology today. 
38. Hodgkin’s Lymphoma Therapy: Past, Present, and Future. Rathore, M Kadin and B. 2010, NIH Public 
Access, pp. 2891–2906. 
39. Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in 
Standard of Care. Böll, Theodoros P Vassilakopoulos and Boris. 2019, European Oncology and 
Haematology. 
40. Brentuximab Vedotin (SGN-35). Jessica Katz, John E. Janik, and Anas Younes. 2011, Clinic Cancer 
Research. 
41. High numbers of active caspase 3–positive Reed-Sternberg cells in pretreatment biopsy specimens of 
patients with Hodgkin disease predict favorable clinical outcome. Danny F. Dukers, Chris J. L. M. Meijer, 
Rosita L. ten Berge, Wim Vos, Gert J. Ossenkoppele, and Joost J. Oudejans. 2016, Blood. 
42. cIAP2 is highly expressed in Hodgkin–Reed–Sternberg cells and inhibits apoptosis by interfering with 
constitutively active caspase-3. Horst Dürkop, Burkhard Hirsch. 2006, Molecular Medicine. 
43. Targeting ADAM10 in Cancer and Autoimmunity. Timothy M. Smith Jr., Anuj Tharakan and Rebecca 
K. Martin. 2020, Frontiers in Immunology. 
44. High numbers of active caspase 3–positive Reed-Sternberg cells in pretreatment biopsy specimens of 
patients with Hodgkin disease predict favorable biopsy specimens of patients with Hodgkin disease predict 
favorable biopsy specimens of patients with Hodgki. Danny F. Dukers, Chris J. L. M. Meijer, Rosita L. ten 
Berge, Wim Vos, Gert J. Ossenkoppele, and Joost J. Oudejans.  
31 
 
45. Williams, S. J. Enna and M. Defining the Role of Pharmacology in the Emerging World of Translational 
Research. Pharmacology and Translational Research. 2009. 
46. Experimental Models as Refined Translational Tools for Breast Cancer Research. Eduardo Costa, Tânia 
Ferreira-Gonçalves, Gonçalo Chasqueira, António S. Cabrita, Isabel V. Figueiredo, and Catarina Pinto 
Reis. 2020, Scientia Pharmaceutica. 
47. The flaws and human harms of animal experimentation. A., Akhtar. 2015, Camb and Health Ethics. 
48. Emerging tumor spheroids technologies for 3D in vitro cancer modeling. 26. Rodrigues T, Kundu B, 
Silva-Correia J, Kundu SC, Oliveira JM, Reis RL, Correlo VM. 2017, Pharmacol Ther. 
49. Elizaveta V. Koudan, 1 Janetta V. Korneva,2 Pavel A. Karalkin,1 Irina S. Gladkaya,1 Anna A. 
Gryadunova,1 Vladimir A. Mironov,1 Yusef D. Khesuani,1 and Elena A. Bulanova. The Scalable 
Standardized Biofabrication of Tissue Spheroids from Different Cell Types Using Nonadhesive Technology. 
3D PRINTING AND ADDITIVE MANUFACTURING. 2017. 
50. Application of tissue engineering to the immune system: development of artificial lymph node. 
TomCupedo, AbrahamStroock and MarkColes. 2012, Frontiers in Immunology. 
51. Spheroid-based drug screen: considerations and practical approach. Juergen Friedrich, Claudia Seidel, 
Reinhard Ebner & Leoni A Kunz-Schughart. 2009, Nature Protocols. 
52. Insight On Colorectal Carcinoma Infiltration by Studying Perilesional Extracellular Matrix. Manuela 
Nebuloni, Luca Albarello, Annapaola Andolfo, Cinzia Magagnotti, Luca Genovese, Irene Locatelli, 
Giovanni Tonon, Erika Longhi, Pietro Zerbi, Raffaele Allevi, Alessandro Podestà, Luca Puricelli, Paolo 
Milani, Armando Soldarini, Andrea Salonia & Massimo Alfano. 2016, Scientifica Reports. 
53. Calcitonin Receptor-Like Receptor and Receptor Activity Modifying Protein 1 in the rat dorsal horn: 
localization in glutamatergic presynaptic terminals containing opioids and adrenergic α2C receptors. Juan 
Carlos G. Marvizón, Orlando A. Pérez, Bingbing Song, Wenling Chen, Nigel W. Bunnett, Eileen F. Grady, 
and Andrew J. Todd. 2007, Neuroscience. 
54. CD30: expression and function in health and disease. Watanabe, Ryouichi Horie and Toshiki. 1998, 
Immunology. 
55. Ki-67: more than a proliferation marker. Kaufman, Xiaoming Sun and Paul D. 2018, Chromosoma. 
56. Framing cancer progression: influence of the organ- and tumour-specific matrisome. Erler, Maria 
Rafaeva and Janine T. FEBS Journal 2019. 
57. Linearized texture of three-dimensional extracellular matrix is mandatory for bladder cancer cell 
invasion. Massimo Alfano, Manuela Nebuloni, Raffaele Allevi, Pietro Zerbi, Erika Longhi, Roberta 
Lucianò, Irene Locatelli, Angela Pecoraro, Marco Indrieri, Chantal Speziali, Claudio Doglioni, Paolo 
Milani, Francesco Montorsi & Andrea Salonia. 2016, Nature. 
 
 
